arsenic trioxide has been researched along with sulindac in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brown, SL; Jiang, TT; Kim, JH | 1 |
| Jeong, ET; Kim, EJ; Kim, HR; Kim, SJ; Park, C; Park, R; So, HS; Yang, SH; Youn, MJ | 1 |
| An, S; Choe, TB; Hong, SI; Jin, HO; Kim, JI; Kwon, TJ; Lee, HC; Lee, SJ; Park, IC; Park, MJ; Rhee, CH; Seo, SK; Woo, SH; Yoo, DH; Yoon, SI | 1 |
| An, S; Choe, TB; Hong, SI; Jin, HO; Kim, ES; Kim, JI; Lee, HC; Lee, SJ; Park, IC; Rhee, CH; Seo, SK; Woo, SH; Yoo, DH | 1 |
| Cheong, HJ; Kim, SJ; Lee, HR; Lee, NS; Park, HS; Won, JH | 1 |
| Jang, HY; Jeong, ET; Jo, HJ; Kim, EJ; Kim, HJ; Kim, HR; Lee, KK; Park, JH; Shim, H; Yang, SH | 1 |
| Arkusz, J; Ferlińska, M; Gradecka-Meesters, D; Smok-Pieniążek, A; Stańczyk, M; Stępnik, M | 2 |
1 review(s) available for arsenic trioxide and sulindac
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for arsenic trioxide and sulindac
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; In Vitro Techniques; Lung Neoplasms; Oxides; Sulindac; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2004 |
Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Flow Cytometry; Growth Inhibitors; Humans; Hydrogen Peroxide; Lung Neoplasms; Oxides; Sulindac | 2006 |
Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Oxides; Reactive Oxygen Species; Sulindac; Survivin | 2006 |
A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation.
Topics: Acetylcysteine; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Drug Synergism; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Oxides; Phosphorylation; Reactive Oxygen Species; Signal Transduction; Sulindac | 2008 |
Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-kappaB in HCT116 colon cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 8; Cell Proliferation; Drug Synergism; HCT116 Cells; Humans; I-kappa B Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; Phosphorylation; Sulindac | 2008 |
Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; DNA Damage; Enzyme Inhibitors; Flow Cytometry; G1 Phase; Heme Oxygenase-1; Histones; Humans; Hydrogen Peroxide; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Oxidative Stress; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Reactive Oxygen Species; Sulindac; Tumor Cells, Cultured | 2008 |
Sulindac and its metabolites: sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Lymphocytes; Membrane Potential, Mitochondrial; Mice; NF-kappa B; Oxides; Propidium; Staining and Labeling; Sulindac | 2011 |
Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leu
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Glutathione; Humans; Leukemia; Mitogen-Activated Protein Kinases; Oxidative Stress; Oxides; Reactive Oxygen Species; Signal Transduction; Sulindac | 2012 |